About Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals is a company based in Vancouver (Canada) founded in 2012 by James Helliwell.. Eupraxia Pharmaceuticals has raised $2.44 million across 10 funding rounds from investors including SVB and National Research Council Canada. Eupraxia Pharmaceuticals operates in a competitive market with competitors including Formation Bio, Flexion Therapeutics, MRM Health, TissueGene and Symic Biomedical, among others.
- Headquarter Vancouver, Canada
- Founders James Helliwell
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Eupraxia Pharmaceuticals, Inc.
-
Annual Revenue
$0 (USD)0as on Dec 31, 2024
-
Net Profit
$-24.28 M (USD)8.27as on Dec 31, 2024
-
EBITDA
$-25.55 M (USD)2.44as on Dec 31, 2024
-
Total Equity Funding
$2.44 M (USD)
in 10 rounds
-
Latest Funding Round
$32 M (USD), Post-IPO
Oct 31, 2024
-
Investors
SVB
& 1 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals is a publicly listed company on the TSX with ticker symbol EPRX in Canada, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Funding Insights of Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals has successfully raised a total of $2.44M across 10 strategic funding rounds. The most recent funding activity was a Post-IPO round of $32 million completed in October 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 10
- Last Round Post-IPO — $32.0M
-
First Round
First Round
(31 Aug 2012)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2024 | Amount | Post-IPO - Eupraxia Pharmaceuticals | Valuation |
investors |
|
| Aug, 2023 | Amount | Post-IPO - Eupraxia Pharmaceuticals | Valuation |
investors |
|
| Nov, 2021 | Amount | Grant - Eupraxia Pharmaceuticals | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include SVB and National Research Council Canada. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Scientific and technological research is conducted for Canada's benefit.
|
Founded Year | Domain | Location | |
|
Banking services are provided to innovative companies, investors, and individuals.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Eupraxia Pharmaceuticals
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Eupraxia Pharmaceuticals
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Eupraxia Pharmaceuticals Comparisons
Competitors of Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Formation Bio, Flexion Therapeutics, MRM Health, TissueGene and Symic Biomedical, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
AI-powered drug discovery platform for various diseases
|
|
| domain | founded_year | HQ Location |
Developer of therapies for the treatment of musculoskeletal disorders
|
|
| domain | founded_year | HQ Location |
Developer of optimized consortia therapeutics targeting inflammatory, CNS, and metabolic diseases
|
|
| domain | founded_year | HQ Location |
Regenerative cell therapies for orthopedic diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developer of compounds to protect against tissue degradation and promote healing during illness or injury
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Eupraxia Pharmaceuticals
Frequently Asked Questions about Eupraxia Pharmaceuticals
When was Eupraxia Pharmaceuticals founded?
Eupraxia Pharmaceuticals was founded in 2012.
Where is Eupraxia Pharmaceuticals located?
Eupraxia Pharmaceuticals is headquartered in Vancouver, Canada. It is registered at Vancouver, British Columbia, Canada.
Who is the current CEO of Eupraxia Pharmaceuticals?
James Helliwell is the current CEO of Eupraxia Pharmaceuticals. They have also founded this company.
Is Eupraxia Pharmaceuticals a funded company?
Eupraxia Pharmaceuticals is a funded company, having raised a total of $2.44M across 10 funding rounds to date. The company's 1st funding round was a Grant of $700K, raised on Aug 31, 2012.
What does Eupraxia Pharmaceuticals do?
Eupraxia Pharmaceuticals is a pharmaceutical company that has a proprietary drug delivery platform. The technology encapsulates pharmaceutical microparticles in a customizable polymer shell that can extend drug release from days to months. The company works on the existing drugs and uses its injectable drug delivery platform for targeted therapies. It also has preclinical and development phase candidates for chronic pain, anesthesia, diabetic macular edema, and infections. The companys lead product candidate, EP-104IAR (phase I clinical trial) is a sustained-release product of the anti-inflammatory, fluticasone propionate for pain relief for patients with osteoarthritis. It also has a phase 1 candidate for veterinary health. In 2016, the company has entered into a license agreement with Auritec under which Eupraxia licensed the Plexis platform technology and intellectual property rights from Auritec for the sustained delivery of corticosteroids.
Who are the top competitors of Eupraxia Pharmaceuticals?
Eupraxia Pharmaceuticals's top competitors include Flexion Therapeutics, Formation Bio and ARTHEx.
Is Eupraxia Pharmaceuticals publicly traded?
Yes, Eupraxia Pharmaceuticals is publicly traded on TSX under the ticker symbol EPRX.
Who are Eupraxia Pharmaceuticals's investors?
Eupraxia Pharmaceuticals has 2 investors. Key investors include SVB, and National Research Council Canada.
What is Eupraxia Pharmaceuticals's ticker symbol?
The ticker symbol of Eupraxia Pharmaceuticals is EPRX on TSX.